J Korean Soc Endocrinol.  2006 Jun;21(3):189-191. 10.3803/jkes.2006.21.3.189.

RANK-Fc Gene Therapy in Mouse Model of Osteoporosis

• Chung HY

• KMID: 2200730
• DOI: http://doi.org/10.3803/jkes.2006.21.3.189

Abstract

No abstract available.

MeSH Terms

Animals
Genetic Therapy*
Mice*
Osteoporosis*

Reference

1. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int. 1981. 33:349–351.

2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998. 93:165–176.

3. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997. 89:309–319.

4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999. 20:345–357.

5. Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003. 14:251–263.

6. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003. 111:1221–1230.

7. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Splesberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999. 140:4382–4389.

8. Locklin RM, Khosla S, Turner RT, Riggs B. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 2003. 89:180–190.

9. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999. 402:304–309.

10. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003. 9:1436–1441.

11. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 2001. 61:1637–1644.

12. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004. 292:490–495.

13. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F. RANKL/RANK/OPG: New therapeutic targets in bone tumors and associated osteolysis. Biochimica Biophy Acta. 2004. 1704:49–57.

14. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001. 16:348–360.

15. Emery JG, McDonnell P, Burke MB. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998. 273:14363–14367.

16. Kim D, Shin CS. Retrovirus mediated gene transfer of RANK-Fc ameliorates bone loss in a mouse ovariectomy model of osteoporosis. J Kor Soc Endocrinol. 2006. 21:192–203.

17. Turgeman G, Aslan H, Gazit Z, Gazit D. Cell-mediated gene therapy for bone formation and regeneration. Curr Opin Mol Ther. 2002. 4:390–394.

18. Liberman JR, Daluiski A, Stevenson S. The effect of regional gene therapy with bone morphogenetic protein-2 producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am. 1999. 81:905–917.

19. Baltzer AW, Whalen JD, Wooley P, Latterman C, Truchan LM, Robbins PD, Evans CH. Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene Ther. 2001. 8:1770–1776.

20. Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther. 2001. 3:197–205.

21. Evans CH, Ghivizzani SC, Herndon JH, Robbins PD. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg. 2005. 13:230–242.